Highlights and Quick Summary
- Net Debt/EBITDA for the quarter ending September 30, 2022 was 4.15 (a -64.3% decrease compared to previous quarter)
- Year-over-year quarterly Net Debt/EBITDA decreased by -11314.32%
- Annual Net Debt/EBITDA for 2021 was 6.06 (a -142.65% decrease from previous year)
- Annual Net Debt/EBITDA for 2020 was -14.21 (a 207.86% increase from previous year)
- Annual Net Debt/EBITDA for 2019 was -4.62 (a 60.12% increase from previous year)
Visit stockrow.com/BBLG
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Net Debt/EBITDA of Bone Biologics Corp.
Most recent Net Debt/EBITDAof BBLG including historical data for past 10 years.Interactive Chart of Net Debt/EBITDA of Bone Biologics Corp.
Bone Biologics Corp. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | 4.15 | 11.62 | 8.86 | – |
| 2021 | -0.04 | -55.55 | -53.85 | -65.51 | 6.06 |
| 2020 | – | -56.8 | -79.54 | -86.85 | -14.21 |
| 2019 | – | – | – | 0.0 | -4.62 |
| 2018 | – | – | – | – | -2.88 |
| 2017 | – | – | – | – | -2.87 |
| 2016 | – | – | – | – | -0.4 |
Business Profile of Bone Biologics Corp.
Sector: Healthcare
Industry: Medical Devices